European Society of Cardiology
Skip navigation links
Home
About the ESC
Membership
Communities
Congresses
Education
Guidelines & Surveys
Journals
Initiatives
Welcome to the European Society of Cardiology. Our mission: to reduce the burden of cardiovascular disease in Europe
 

Angiotensin Converting Enzyme Inhibitors in Cardiovascular Disease (Expert Consensus Document on)

ESC Clinical Practice Guidelines

Topics: Clinical pharmacology

22/03/2004 00:00:00

Current versions available to download

Publication dateVersionsReferencesSize
2004Full TextEHJ 2004;25:1454-1470301 KB

Current translated versions available to download:

Authors

J. Lopez-Sendon FESC (Chairperson), K. Swedberg FESC, J. McMurray FESC, J. Tamargo FESC, A. P. Maggioni FESC, H. Dargie FESC, M. Tendera FESC, F. Waagstein FESC, J. Kjekshus FESC, P. Lechat FESC, C. Torp-Pedersen FESC

Endorsed by:

Table of contents: Full Text (ESC Clinical Practice Guidelines)

Pharmacology

  • Definition
  • ACE-inhibitor classification
  • Pharmacokinetic profile
  • Mechanism of action
  • Effects of ACE-inhibitors: Haemodynamic effects, Neurohormonal effects, Antiproliferative effects, Renal effects, Other effects, Effects on fibrinolytic balance
  • Side effects
  • Contraindications
  • Drug interactions
  • Dosing

Clinical efficacy and practical use

  • Heart failure: Target dose, ACE-I compared with angiotensin, receptor blockers
  • Asymptomatic left ventricular systolic dysfunction, Diastolic failure
  • Acute myocardial infarction
  • Hypertension
  • Secondary prevention and high-risk of cardiovascular disease
  • Prevention of sudden cardiac death

Previous versions

A complete list of ESC Clinical Practice Guidelines (current and previous versions) endorsed by ESC National Society Members is available here